Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15315675 | 1.00 | SIGMAR1 (0.52) | SIGMAR1DRD4CHRM2CHRM3ALDH1A1 | |
| SCHEMBL11958053 | 0.88 | DRD4 (0.56) | SIGMAR1DRD4ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL11779683 | 0.86 | CHRM2 (0.46) | SIGMAR1DRD4CHRM2CHRM3ALDH1A1 | |
| SCHEMBL7964674 | 0.83 | MAPK1 (0.48) | DRD4CHRM2CHRM3CYP2D6DRD2 | |
| SCHEMBL4159182 | 0.83 | DRD4 (0.50) | SIGMAR1DRD4CHRM2CHRM3ALDH1A1 | |
| SCHEMBL4159183 | 0.83 | DRD4 (0.50) | SIGMAR1DRD4CHRM2CHRM3ALDH1A1 | |
| SCHEMBL9307239 | 0.83 | MAPK1 (0.43) | DRD4CHRM2CHRM3CYP2D6SMN1; SMN2 | |
| SCHEMBL11958071 | 0.81 | CNR1 (0.53) | SIGMAR1DRD4ALDH1A1POLBBCHE | |
| SCHEMBL16226782 | 0.81 | SIGMAR1 (0.55) | SIGMAR1DRD4CHRM2CHRM3ALDH1A1 | |
| SCHEMBL13134572 | 0.80 | DRD2 (0.54) | SIGMAR1DRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | SIGMAR1 117/4885DRD4 1007/4885CHRM2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.